Many demands are currently being made to the new federal government with regard to the future funding of research and science. The transfer to application is particularly important, explains Rafael Laguna de la Vera.

AATec Medical receives four Million from SPRIND and Family Offices to prepare the drug candidate ATL-105 for clinical development in lead indication non-CF related bronchiectasis.

In an interview, challenge officer Jano Costard talks about the competition that transforms ideas into breakthrough innovations.